Skip to main content

Table 6 Overall response rate and disease-control rate (n = 66)

From: Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

Characteristic ORR (%) P-value DCR (%) P-value
Age <60
≥ 60
35.3
31.6
.784 61.8
68.4
.628
Sex Male
Female
30.3
40.0
.470 69.7
55.0
.279
  Pancreas 35.7   71.4  
Origin GI 30.8 1.000 38.5 .055
  Lung 0.0   0.0  
Liver metastasis Absent
Present
58.8
22.2
.009 82.4
55.6
.072
  1 33.3   66.7  
  2-3 44.4   66.7  
Grade    .460   .433
  Large 40.0   40.0  
  Small 33.3   100.0  
  24-hour urine 5-HIAA (μmol/day) <31.4
≥ 31.4
0.0
33.3
.455 20.0
66.7
.242
Biomarkers  
  Serum NSE (nmol/l) <1.0
≥ 1.0
0.0
55.6
.034 28.6
77.8
.126
  IFN 23.1   53.8  
Regimen Somatostatin-analogue* 0.0 .400 0.0 .079
  Chemotherapy 39.5   71.1  
  1. ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon
  2. *Somatostatin-analogue was given to only 2 patients.